The oncology and immuno-oncology drug discovery landscape is dynamic, characterized by both unprecedented advances and daunting challenges. In recent years, breakthrough discoveries have propelled the emergence of targeted therapies, immunotherapies, and innovative modalities such as CAR-T cell therapies, antibody-drug conjugates (ADCs), and degraders (e.g., PROTACs and molecular glues), which have revolutionized treatment approaches. These precision medicine approaches hold the promise of tailored therapies that minimize side effects and maximize therapeutic efficacy.
Amid these advances, however, significant challenges remain. Cancer is a complex and heterogeneous disease with multiple molecular drivers and mechanisms of resistance. Identifying and validating druggable targets amidst this complexity is no small feat. In addition, the tumor microenvironment presents formidable barriers to treatment efficacy, often promoting immune evasion and therapeutic resistance (e.g., tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), resistance to platinum-based drugs like cisplatin in ovarian cancers, immunotherapy resistance in some patients due to loss of antigen presentation, upregulation of alternative immune checkpoints, or recruitment of immunosuppressive cells like regulatory T cells or myeloid-derived suppressor cells).
Comprehensive solutions for multiple oncology therapeutic modalities
Eurofins Discovery’s commitment to advancing oncology and immuno-oncology drug discovery is reflected in our comprehensive suite of solutions designed to evaluate a wide range of therapeutic modalities (e.g., small molecules, peptides, protein degraders, antibody-drug conjugates, antibodies, antisense oligonucleotides, cell & gene therapies). From therapies targeting key oncogenes to immunotherapies to modulation of the tumor microenvironment, we provide in-depth support for multiple anti-cancer strategies.
Broadest oncology-related target and translational panels
Harnessing the power of precision medicine, we offer the broadest range of target-based and translational assays producing high-quality data for efficient anti-cancer drug discovery strategies. Whether you are evaluating targets such as kinases, Ras, SH2 domains, helicase family members, STING, PARP, ENPP, or any other molecular targets, we provide the tools you need to break new ground in cancer treatment. Not only do we have the largest panel of binding and enzymatic/functional assays covering the kinome, but our phenotypic and translationally relevant solutions, such as OncoPanel® and BioMAP®, can help drive programs forward with confidence and increase the chance of approval. As the landscape of cancer research evolves, so do our capabilities. Our commitment to innovation ensures that you have access to the latest advances in the field.
The need for integrated oncology solutions
With the growing challenges in oncology and immuno-oncology drug discovery and development, the need for integrated solutions has never been more apparent. Traditional drug discovery models with their siloed approach are no longer sufficient to effectively address the complexities of cancer biology and therapeutic development.
What sets us apart is our deep commitment to expertise and trust to develop a strong partnership with you:
Our team of seasoned scientists and program managers has a wealth of experience, including developing treatments in oncology that have made a tangible impact in the fight against cancer. Our experts in oncology and immuno-oncology have a proven track record of progressing candidates into the clinic and providing data-driven insights toward BLA/MAA or IND/CTA success. We have developed an extensive portfolio of assays, services, and products that cater to the discovery and development of small molecules, biologics, epigenetic modulators, PROTACs, and CAR-T therapies. Skilled at conducting successful oncology drug discovery programs, we bring unparalleled insight and expertise to every project – and have a number of case studies that illustrate this point.
Partner with us for your oncology & immuno-oncology programs
When you partner with us, you are not just gaining access to a suite of robust, integrated solutions; you are entrusting your research to a team of experts that is dedicated to driving meaningful progress in oncology and immuno-oncology therapeutic discovery and development.
- Proven Track Record: Our team includes individuals who have played key roles in the discovery, development, and approval of cancer treatments currently used in clinical practice.
- Significant Insight: We have a deep understanding of cancer biology and therapeutic mechanisms, allowing us to develop innovative strategies that are tailored to meet your specific research needs.
- Collaborative Approach: We believe in fostering partnerships, working hand-in-hand with our clients to achieve common goals and milestones. We would like you to view us as an extension of your drug discovery team!
- Holistic Support: We help design and set up screening cascades to identify, optimize, and refine suitable molecules for IND candidate selection, predict genomic biomarkers of response, evaluate broader biological consequences of treatment, and even identify new cancer indications for existing compounds (drug repurposing). Our experts provide comprehensive support at every stage of your research journey, including the use of our proprietary DiscoveryAI™ ADMET tool and clinically relevant BioMAP platform, and work toward providing the best candidate molecules possible, while also minimizing potential safety and toxicity issues.
